Mucinous ovarian cancer

被引:52
作者
Harrison, M. L. [1 ]
Jameson, C. [2 ]
Gore, M. E. [1 ]
机构
[1] Royal Marsden Hosp, Dept Med, London SW3 6JJ, England
[2] Royal Marsden Hosp, Dept Histopathol, London SW3 6JJ, England
关键词
chemotherapy; epithelial ovarian cancer; molecular studies; mucinous; pathology;
D O I
10.1111/j.1525-1438.2007.01022.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Mucinous epithelial ovarian cancer (mEOC) accounts for approximately 10% of EOCs. Patients presenting with early-stage disease have an excellent prognosis, however, those with advanced disease have a poor outcome with relative resistance to standard ovarian cancer chemotherapy. Molecular and genetic studies demonstrate differences between mucinous and serous EOC supporting the concept that these tumors develop along separate pathways. Together with the observed differences in clinical behavior and outcome for mEOC, there is a need to develop specific therapeutic strategies for this histologic subtype. The relative rarity of advanced mEOC has resulted in few patients enrolled in major ovarian cancer trials. The results of such trials may not necessarily reflect those specific to mEOC. Separate trials testing alternative chemotherapeutics are required. Metastatic mucinous tumors from other sites such as the gastrointestinal tract may present with ovarian involvement. For all mucinous tumors of the ovary, establishing primary as opposed to metastatic cancers is important. Clinical presentation, tumor markers, histologic, and immunohistochemical features are helpful in distinguishing most cases.
引用
收藏
页码:209 / 214
页数:6
相关论文
共 43 条
  • [1] Kirsten ras mutations in patients with colorectal cancer:: the 'RASCAL II' study
    Andreyev, HJN
    Norman, AR
    Cunningham, D
    Oates, J
    Dix, BR
    Iacopetta, BJ
    Young, J
    Walsh, T
    Ward, R
    Hawkins, N
    Beranek, M
    Jandik, P
    Benamouzig, R
    Jullian, E
    Laurent-Puig, P
    Olschwang, S
    Muller, O
    Hoffmann, I
    Rabes, HM
    Zietz, C
    Troungos, C
    Valavanis, C
    Yuen, ST
    Ho, JWC
    Croke, CT
    O'Donoghue, DP
    Giaretti, W
    Rapallo, A
    Russo, A
    Bazan, V
    Tanaka, M
    Omura, K
    Azuma, T
    Ohkusa, T
    Fujimori, T
    Ono, Y
    Pauly, M
    Faber, C
    Glaesener, R
    de Goeij, AFPM
    Arends, JW
    Andersen, SN
    Lövig, T
    Breivik, J
    Gaudernack, G
    Clausen, OPF
    De Angelis, P
    Meling, GI
    Rognum, TO
    Smith, R
    [J]. BRITISH JOURNAL OF CANCER, 2001, 85 (05) : 692 - 696
  • [2] Berezowski K, 1996, MODERN PATHOL, V9, P426
  • [3] Burger R. A., 2005, P AN M AM SOC CLIN, V23, pS16
  • [4] Cannistra S. A., 2006, P AN M AM SOC CLIN, V24, pS18
  • [5] Cuatrecasas M, 1997, CANCER, V79, P1581, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1581::AID-CNCR21>3.0.CO
  • [6] 2-T
  • [7] Necrosis in 84 ovarian carcinomas: A morphologic study of primary versus metastatic colonic carcinoma with a selective immunohistochemical analysis of cytokeratin subtypes and carcinoembryonic antigen
    DeCostanzo, DC
    Elias, JM
    Chumas, JC
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 1997, 16 (03) : 245 - 249
  • [8] Genetic alterations in ovarian carcinoma: with specific reference to histological subtypes
    Fujita, M
    Enomoto, T
    Murata, Y
    [J]. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2003, 202 (1-2) : 97 - 99
  • [9] k-ras mutation may be an early event in mucinous ovarian tumorigenesis
    Garrett, AP
    Lee, KR
    Colitti, CR
    Muto, MG
    Berkowitz, RS
    Mok, SC
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2001, 20 (03) : 244 - 251
  • [10] Giantonio BJ, 2005, J CLIN ONCOL, V23, p1S